2Kim CK, Park BK, Han JJ, et al. Diffusion-weighted imaging of the prostate at 3T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results[ J ]. J Corn-put Assist Tomogr, 2007, 31 (3) : 449-454.
3Kuhl CK, Jost P, Morakkabati N, et al. Contrast-enhanced MR imaging of the breast at 3.0T and 1.5T in the same patients[J]. Radiology, 2006, 239(6):666-676.
4Beatty JD, Porter BA. ContrastLenhanced breast magnetic reso- nance imaglng: the surgical perspective [ J ]. Am J Surg, 2007, 193 ( 1 ) : 600- 605.
5Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer[J]. Br J Surg, 2005, 92(1 ) : 14-23.
6Kuhl CK, Mielearek P, Klaschik S, et al. Are single time course data useful for differential diagnosis of enhancing lesions in dynamic breast MR imaging? [J]. Radiology, 1999, 211(1): 101- 110.
7Kurosumi M, AkashiTanaka S, Akiyama F, et al. Histopa- thological criteria for assessment of therapeutic response inbreast cancer ( 2007 version) [J]. Breast Cancer, 2008, 15(1): 5-7.
8Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predictingresponse with in vivo 1H MR spectroscopy a pilot study at 4T [J]. Radiology, 2004,233(2):424-431.
9Wasser K, Klein SK, Fink C, et al. Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution [J]. Eur Radiol, 2003, 13(1) 80-87.
10Kvistad KA, Bakken U, Gribbestad IS, et al. Characterizationof neoplastic and normal human breast tissues with in vivo (1) H MR spectroscopy [J]. J Magn Reson Imaging, 1999, 10(2) : 159-164.
